The only pharmacologic treatment for gestational diabetes (GDM) approved by U.S. Food and Drug Administration is insulin. However, due to improved ease of use and lower cost, oral antidiabetic medications, such as glyburide, have been prescribed more commonly than insulin. We investigate glyburide's impact on two adverse perinatal outcomes compared to medical nutritional therapy, the universal first-line therapy, in an observational study of a large, population-based cohort. At the design stage, we employ matching to select comparable treated (received glyburide) and controls (received medical nutritional therapy). Multiple background variables were associated with GDM treatment modality and perinatal outcomes; however, there is ambiguity about which potential variables should be selected for matching. Standard selection methods based on treatment imbalance neglect the variable's relationship with the outcome. Thus, we propose the joint variable importance plot (jointVIP) to guide variable prioritization for this study. These plots enhance variable comparisons via bias curves derived under the omitted variable bias framework and can translate into recommended values for tuning parameters in existing methods. After forming matched pairs, we conduct inference and perform sensitivity analyses to assess the potential role of unmeasured confounding. Understanding glyburide safety can better inform future pharmacologic treatment strategies to manage GDM.
翻译:美国食品和药品管理局批准的唯一妊娠糖尿病药理治疗(GDM)是胰岛素,但是,由于使用方便和费用降低,口服抗糖尿病药物(如甘蓝酸)比胰岛素更加常见。我们调查甘蓝酸对两种不利围产期结果的影响,相对于医疗营养疗法(即全民一线疗法),这是对大规模基于人口的组群的观察性研究。在设计阶段,我们采用匹配方法选择可比较的治疗(收到口服甘油)和控制(收到医疗营养疗法),多种背景变数与GDM治疗模式和围产期结果相关联;然而,对于应选择哪些潜在变数进行配对的情况,有些模糊不清。基于治疗不平衡的标准选择方法忽视了变量与结果的关系。因此,我们提出联合可变重要方案(联合VIP),以指导这项研究的变量排序。在设计阶段,我们采用根据省略的可变偏差框架得出的偏差曲线,通过推荐的参数,加强变量比较,并可以转化为调整现有敏感度分析方法的参数,然后进行匹配的组合后,可以评估。